- Home
- PAR vs CNTA Comparison
PAR vs CNTA Comparison
Compare PAR & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAR | CNTA |
|---|---|---|
| Founded | 1968 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 3.7B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PAR | CNTA |
|---|---|---|
| Price | $36.44 | $25.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $64.00 | $37.70 |
| AVG Volume (30 Days) | 484.6K | ★ 1.2M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $440,451,000.00 | $15,000,000.00 |
| Revenue This Year | $30.40 | N/A |
| Revenue Next Year | $12.01 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 39.88 | ★ 118.88 |
| 52 Week Low | $31.65 | $9.60 |
| 52 Week High | $77.55 | $30.58 |
Technical Indicators
Market Signals| Indicator | PAR | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 51.30 | 41.94 |
| Support Level | $36.48 | $24.17 |
| Resistance Level | $37.88 | $26.01 |
| Average True Range (ATR) | 1.08 | 1.14 |
| MACD | 0.07 | -0.26 |
| Stochastic Oscillator | 42.19 | 18.64 |
Price Performance
Historical ComparisonAbout PAR PAR Technology Corporation
PAR Technology Corp is a foodservice technology company providing omnichannel cloud-based software and hardware solutions to the restaurant industry in three restaurant categories - quick service, fast casual, and table service - and the retail industry, including convenience and fuel retailers (C-Stores). The company's product and service offerings include point-of-sale, customer engagement and loyalty, digital ordering and delivery, operational intelligence, payment processing, hardware, and related technologies, solutions, and services. The company generates revenue from subscription service, Sale of Hardware products, and Professional Service.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.